| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 21.7 | 16.4 |
| Profit before tax | -25.3 | -41.0 |
| Net income | -25.3 | -41.0 |
| EPS (diluted, $ a share) | $-0.16 | $-0.30 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +32.2% |
|---|---|
| Operating margin | -66.1% |
10-Q filed with the SEC, NYSE: ADCT. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
ADC Therapeutics SA: key numbers
- Share price
- $1.25Close, Nov 16
- Market cap
- $160M
- Shares outstanding
- 127.67MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from ADC Therapeutics SA
All →ADC Therapeutics Financial Results
ADC Therapeutics reported Q3 2026 net product revenue of $21 million and highlighted a strategic financial restructuring completed in October that extended its cash runway into 2029. The company also noted multiple upcoming data presentations for ZYNLONTA at the ASH 2026 annual meeting.
- Term
- Q3 2026
“During the third quarter, we made meaningful progress toward strengthening ADC Therapeutics' balance sheet and increasing strategic optionality while advancing clinical opportunities for ZYNLONTA®.”
Ameet Mallik, Chief Executive Officer of ADC Therapeutics
“The upcoming LOTIS-7 Phase 1b and marginal zone lymphoma IIT data at ASH highlights the potential for ZYNLONTA to play an important role in the treatment of r/r DLBCL and indolent lymphomas.”
Mohamed Zaki, M.D., Ph.D., Chief Medical Officer of ADC Therapeutics
ADC Therapeutics Clinical Trial Data
ADC Therapeutics announced updated clinical data for ZYNLONTA from several trials, including the LOTIS-7 Phase 1b study which showed an 88.7% overall response rate and 75.3% complete response rate in relapsed or refractory large B-cell lymphoma. The data, which will be presented at the ASH Annual Meeting, also highlighted a 93% ORR in marginal zone lymphoma and results from the Phase 3 LOTIS-5 study. These findings support the company's plans to advance ZYNLONTA into Phase 3 studies for expanded indications.
ADC Therapeutics Capital Raise of $86.6M
ADC Therapeutics entered into securities purchase agreements for a $86.6 million private placement (PIPE) involving the sale of 12.9 million common shares and 48.1 million pre-funded warrants. The financing included participation from new investor Bain Capital Life Sciences and existing investors Redmile, TCGX, and Nantahala Capital. Proceeds will be used to fund ZYNLONTA pipeline studies and extend the company's cash runway into 2029.
- Value
- $86.6M
- Counterparty
- Bain Capital Life Sciences